Skip to content
Anlon Healthcare logo

Anlon Healthcare

AHCL NSE
₹26.66 +1.26 (+4.96%)
P/E
6.84
View as Markdown
MCP
Close 4 Nov 2026 ₹26.66 +12.69 +90.8% 1Y
Start ₹13.97

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · TTM

ROCE
20.80%
Debt to Equity
0.19
EPS (TTM)
₹3.90
Book Value
₹4.84
Market Cap
—
P/E (TTM)
6.84
P/B
5.51
ROE
18.40%
Dividend Yield
0.00%
EBITDA
₹47.80 Cr
52W High
₹37.24
52W Low
₹10.37
Day Range
₹25.00 – ₹26.67
Volume
50,53,143

Peer Comparison

Healthcare › Pharmaceuticals

Anlon Healthcare peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Anlon Healthcare (this company)
₹26.666.84₹1,372 Cr5.510.00%18.40%20.80%₹280 Cr₹42 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr5.140.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

45 Average

Data confidence 100/100

surveillance:ASM1

Category scores

Quality
40
Weak
Returns, margins, earnings quality 22% weight
Valuation
51
Average
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
72
Strong
Solvency, leverage, coverage 9% weight
Momentum
95
Strong
Trend strength, vol-adjusted 12% weight
Ownership
17
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has reduced debt.

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 220 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3610
OscillatorsBearish360
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
53.01
Neutral
MACD (12,26,9)
−0.06
Bearish
SMA (50)
23.99
Bullish
SMA (200)
16.21
Bullish

As of

Growth Rate

From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
1Y+43.33%

Net profit

Net profit growth by window
1Y+38.10%

Operating cash flow

Operating cash flow growth by window
1YOutflow widened by ₹37 Cr

Operating margin· change in pp

Operating margin growth by window
1Y+1.24 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2025₹120 Cr
Mar 2026₹172 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2025₹21.00 Cr
Mar 2026₹29.00 Cr

Quarterly Results

₹ Cr
AHCL quarterly results, ₹ crore
Particulars Mar 2025Jun 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
48.93
33.3
35.58
50.89
87.56
106
Expenses
31.74
27.06
23.3
35.6
71.97
80.37
Operating Profit
17.19
6.24
12.28
15.29
15.59
25.24
OPM %
35.13%
18.74%
34.51%
30.05%
17.8%
23.9%
Other Income
0.04
0.01
0.2
0.01
0.06
—
Interest
0.91
0.82
1.51
0.57
0.92
0.86
Depreciation
0.83
0.43
0.35
0.29
1.07
—
PBT
15.49
5
10.62
14.44
13.66
23.47
Tax %
−7.49%
29.2%
51.41%
23.34%
39.39%
26.84%
Net Profit
16.65
3.55
5.15
11.07
8.28
17.18
EPS (₹)
0.42
0.09
0.1
0.2
0.13
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
AHCL profit and loss, annual, ₹ crore
Particulars Mar 2025Mar 2026
Sales
120
172
Expenses
88
124
Operating Profit
32
48
OPM %
27%
28%
Other Income
0
0
Interest
4
4
Depreciation
2
2
PBT
27
43
Tax %
24%
32%
Net Profit
21
29
EPS (₹)
0.51
0.54
Div. Payout %
0%
0%

Balance Sheet

₹ Cr
AHCL balance sheet, annual, ₹ crore
Particulars Mar 2025Mar 2026
Equity Capital
40
53
Reserves
41
177
Borrowings
67
44
Other Liabilities
34
100
Total Liabilities
181
374
Fixed Assets
23
58
CWIP
0
0
Investments
1
1
Other Assets
158
315
Total Assets
181
374

Cash Flow

₹ Cr
AHCL cash flow, annual, ₹ crore
Particulars Mar 2025Mar 2026
Operating
−22
−59
Investing
2
−36
Financing
19
118
Net Cash Flow
−1
23
Free Cash Flow
−19
−95
CFO/EBITDA
−85
−114

Ratios

AHCL financial ratios, annual
Particulars Mar 2025Mar 2026
Debtor Days
228
220
Inventory Days
246
393
Days Payable
96
147
Cash Conversion Cycle
377
467
Working Capital Days
292
417
ROCE %
—
21%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Anlon Healthcare insights

65 extracted metrics across FY23–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 52.68%
  • Public 29.24%
  • Others 16.78%
  • FIIs 1.00%
  • DIIs 0.30%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Anlon Healthcare

What does Anlon Healthcare Ltd do?
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).
Where is Anlon Healthcare Ltd (AHCL) listed?
Anlon Healthcare Ltd trades as AHCL on the NSE and under code 544497 on the BSE.
Which sector does Anlon Healthcare Ltd belong to?
Anlon Healthcare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Anlon Healthcare Ltd?
Anlon Healthcare Ltd trades at a PE ratio of 6.84 as of 4 Nov 2026, on earnings per share of ₹3.9, against a book value of ₹4.84 per share.
What is the 52-week high and low of Anlon Healthcare Ltd?
Over the last 52 weeks Anlon Healthcare Ltd has traded between ₹10.37 and ₹37.24 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Anlon Healthcare Ltd?
Anlon Healthcare Ltd reported a return on equity of 18.40%. Its debt-to-equity ratio is 0.19.

Company Information

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).

Website anlon.in
CEO Mr. Punitkumar Rameshbhai Rasadia
Listed 3 Sep 2025
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AHCL.md for Anlon Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month